Form 4: Travere Therapeutics CEO Sells Shares
Insider Transaction (Form 4)
Eric M Dube, CHIEF EXECUTIVE OFFICER and a Director of Travere Therapeutics, Inc., sold 400,000 shares of common stock on September 15, 2026.
Summary
- Option exercise/conversion: acquired 95,666 Common Stock at $23.34 ($2,232,844) on September 15, 2026; holds 528,552 after (Direct).
- Open-market sale: disposed of 63,498 Common Stock at $61.99 ($3,936,527) on September 15, 2026; holds 465,054 after (Direct).
- Open-market sale: disposed of 28,796 Common Stock at $62.66 ($1,804,222) on September 15, 2026; holds 436,258 after (Direct).
- Open-market sale: disposed of 3,102 Common Stock at $63.64 ($197,422) on September 15, 2026; holds 433,156 after (Direct).
- Open-market sale: disposed of 270 Common Stock at $65.31 ($17,634) on September 15, 2026; holds 432,886 after (Direct).
- Option exercise/conversion: acquired 195,841 Common Stock at $23.34 ($4,570,929) on September 16, 2026; holds 628,727 after (Direct).
- Open-market sale: disposed of 99,716 Common Stock at $63.26 ($6,307,964) on September 16, 2026; holds 529,011 after (Direct).
- Open-market sale: disposed of 96,125 Common Stock at $63.64 ($6,117,289) on September 16, 2026; holds 432,886 after (Direct).
- Option exercise/conversion: acquired 108,493 Common Stock at $23.34 ($2,532,227) on September 17, 2026; holds 541,379 after (Direct).
- Open-market sale: disposed of 101,691 Common Stock at $64.59 ($6,567,876) on September 17, 2026; holds 439,688 after (Direct).
- Open-market sale: disposed of 6,802 Common Stock at $64.95 ($441,795) on September 17, 2026; holds 432,886 after (Direct).
- Option exercise/conversion: disposed of 95,666 Employee stock option (right to buy) on September 15, 2026; holds 304,334 after (Direct).
- Option exercise/conversion: disposed of 195,841 Employee stock option (right to buy) on September 16, 2026; holds 108,493 after (Direct).
- Option exercise/conversion: disposed of 108,493 Employee stock option (right to buy) on September 17, 2026 (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $25,390,729 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Eric M Dube — Director, Officer (CHIEF EXECUTIVE OFFICER)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-15 | Option exercise/conversion | Common Stock | 95,666 | $23 | $2.2M | 528,552 |
| 2026-09-15 | Open-market sale | Common Stock | 63,498 | $62 | $3.9M | 465,054 |
| 2026-09-15 | Open-market sale | Common Stock | 28,796 | $63 | $1.8M | 436,258 |
| 2026-09-15 | Open-market sale | Common Stock | 3,102 | $64 | $197.4K | 433,156 |
| 2026-09-15 | Open-market sale | Common Stock | 270 | $65 | $17.6K | 432,886 |
| 2026-09-16 | Option exercise/conversion | Common Stock | 195,841 | $23 | $4.6M | 628,727 |
| 2026-09-16 | Open-market sale | Common Stock | 99,716 | $63 | $6.3M | 529,011 |
| 2026-09-16 | Open-market sale | Common Stock | 96,125 | $64 | $6.1M | 432,886 |
| 2026-09-17 | Option exercise/conversion | Common Stock | 108,493 | $23 | $2.5M | 541,379 |
| 2026-09-17 | Open-market sale | Common Stock | 101,691 | $65 | $6.6M | 439,688 |
| 2026-09-17 | Open-market sale | Common Stock | 6,802 | $65 | $441.8K | 432,886 |
| 2026-09-15 | Option exercise/conversion | Employee stock option (right to buy) | 95,666 | — | — | 304,334 |
| 2026-09-16 | Option exercise/conversion | Employee stock option (right to buy) | 195,841 | — | — | 108,493 |
| 2026-09-17 | Option exercise/conversion | Employee stock option (right to buy) | 108,493 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-15 | Option exercise/conversion (95,666 shares) |
| 2026-09-15 | Open-market sale (63,498 shares) |
| 2026-09-15 | Open-market sale (28,796 shares) |
| 2026-09-15 | Open-market sale (3,102 shares) |
| 2026-09-15 | Open-market sale (270 shares) |
| 2026-09-16 | Option exercise/conversion (195,841 shares) |
| 2026-09-16 | Open-market sale (99,716 shares) |
| 2026-09-16 | Open-market sale (96,125 shares) |
| 2026-09-17 | Option exercise/conversion (108,493 shares) |
| 2026-09-17 | Open-market sale (101,691 shares) |
| 2026-09-17 | Open-market sale (6,802 shares) |
| 2026-09-15 | Option exercise/conversion (95,666 shares) |
| 2026-09-16 | Option exercise/conversion (195,841 shares) |
| 2026-09-17 | Option exercise/conversion (108,493 shares) |
Keywords
insider transaction, Form 4, TVTX, Travere Therapeutics, Inc., bearish, Eric M Dube
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.